Epidemiology, clinical manifestations and efficiency of different methods of treatment of acromegaly according to the united russian registry of patients with pituitary tumors

  • Authors: Belaya Z.E.1, Golounina O.O.2, Rozhinskaya L.Y.3, Melnichenko G.A.3, Isakov M.А.3, Lutsenko A.S.3, Alekseeva T.4, Zenkova T.S.3, Przhiyalkovskaya E.G.3, Panyushkina G.5, Ilukhina O.6, Ivanova E.7, Krishtal E.8, Vachygova A.8, Pigarova E.A.3, Dzeranova L.K.3, Marova E.I.9, Arapova S.D.3, Mamedova E.O.3, Grebennikova T.A.3, Antsiferov M.B.10, Dreval A.V.11, Dedov I.I.3
  • Affiliations:
    1. Endocrinology Research Center
    2. I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
    3. Endocrinology Research Centre
    4. Endocrinological dispansery Health Care Department, Moscow
    5. Voronezh Regional Clinical Hospital #1, Voronezh
    6. Orenburg Regional Clinical Hospital #2, Orenburg
    7. Repiblic hospital named after V.A. Baranov, Petrozavodsk
    8. Volgograd Regional Clinical Hospital #1, Volgograd
    9. Endocrinology Research Center of the Health Ministry
    10. State Moscow Endocrine Dispensary
    11. Moscow Area Moscows regional research clinical institute n.a. M.F. Vladimirskiy
  • URL: https://probl-endojournals.ru/probl/article/view/10333
  • DOI: https://doi.org/10.14341/probl10333
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Abstract


Background: The registry is the main source of information about patients with acromegaly for assessing the quality of medical care, treatment effectiveness, determining the compliance of real clinical practice with existing standards and patient management.

Aims: To analyze epidemiological, demographic and clinical characteristics of acromegaly in the Russian Federation and the effectiveness of various treatment methods.

Materials and methods: The object of the study was the database of Russian registry of patients with pituitary tumors with specific analysis of patients with acromegaly only. We analyzed the data of 4114 patients with acromegaly stored on the online system in February 2019.

Results: Based on the data 32% of patients had complete clinical and laboratory remission of acromegaly; percentage of patients with no remission was 68%, among them 22.5% had significant improvements in clinical symptoms and a decrease in GH and IGF1 without IGF1 normalization. The average age of patients at the onset of the disease was 42.7 years and at diagnosis – 45.8 years. Men to women ratio was 1:2.6.  In patients with acromegaly hypopituitarism was registered in 14.7% of cases and among them hypothyroidism (66%) and hypogonadism (52%) were registered more often. Among other complications the leading were diabetes mellitus (15.7%) and acromegalic arthropathy (15%). The proportion of patients receiving neurosurgical treatment increased from 35.7% to 49.6% in 2012-2019; the percentage of patients undergoing radiation therapy decreased significantly from 17.7% in 2012 to 0.8% in 2019. Remission was achieved in 40.47% after neurosurgery and 28.95% after medical treatment as a first line therapy p<0.01. The number of patients receiving medical treatment at the time of the study was 1209. Among them 51% of patients treated with long-acting lanreotide and 24% receiving long-acting octreotide achieved remission (p<0.0001)

Conclusions: The remission rate of acromegaly remains suboptimal despite increased surgical activity, which corresponds to global trends. Long-acting lanreotide was significantly superior versus long-acting octreotide in the rate of acromegaly remission, which does not correspond with clinical trials and can be explained by the usage of different generic forms of octreotide, regional differences in medical supply and difficulties in long-acting octreotide injection vs lanreotide.


About the authors

Zhanna E. Belaya

Endocrinology Research Center

Email: jannabelaya@gmail.com
ORCID iD: 0000-0002-6674-6441
SPIN-code: 4746-7173

Russian Federation, 11, Dm. Ulyanova street, Moscow, 117036

MD, PhD, Professor

Olga O. Golounina

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: olga.golounina@mail.ru
ORCID iD: 0000-0003-2320-1051
SPIN-code: 7793-2123

Russian Federation, 8 Trubetskaya street, 119991 Moscow

Student, Medical faculty

Liudmila Y. Rozhinskaya

Endocrinology Research Centre

Email: lrozhinskaya@gmail.com
ORCID iD: 0000-0001-7041-0732
SPIN-code: 5691-7775

Russian Federation, 117036, Moscow, ul. Dm. Ul'yanova 11

MD, Professor, Chief Researcher of the
Department of Neuroendocrinology and Osteopathy

Galina A. Melnichenko

Endocrinology Research Centre

Email: teofrast2000@mail.ru
ORCID iD: 0000-0002-5634-7877
SPIN-code: 5873-2280

Russian Federation, 11 Dm. Ulyanova street, 117036 Moscow

MD, PhD, Professor

Michail А. Isakov

Endocrinology Research Centre

Author for correspondence.
Email: m.isakov@aston-health.com
ORCID iD: 0000-0001-9760-1117
SPIN-code: 5870-8933

Russian Federation, 11, Dm. Ulyanova street, Moscow, 117036

PhD

Alexander S. Lutsenko

Endocrinology Research Centre

Email: some91@mail.ru
ORCID iD: 0000-0002-9314-7831
SPIN-code: 4037-1030

Russian Federation, 11, Dm. Ulyanova street, Moscow, 117036

research scientist of neuroendocrinology and bone diseases department

Tatiana Alekseeva

Endocrinological dispansery Health Care Department, Moscow

Email: mamamarka@yandex.ru

Russian Federation

Tatiana S. Zenkova

Endocrinology Research Centre

Email: tatianazenkova@rambler.ru
ORCID iD: 0000-0002-7724-1617
SPIN-code: 2154-5837

Russian Federation, 11 Dm. Ulyanova street, 117036 Moscow, Russia

MD, PhD

Elena G. Przhiyalkovskaya

Endocrinology Research Centre

Email: przhiyalkovskaya.elena@gmail.com
ORCID iD: 0000-0001-9119-2447
SPIN-code: 9309-3256

Russian Federation, 11, Dm. Ulyanova street, Moscow, 117036

PhD

Galina Panyushkina

Voronezh Regional Clinical Hospital #1, Voronezh

Email: endocrinology@okb.vrn.ru

Russian Federation

Olga Ilukhina

Orenburg Regional Clinical Hospital #2, Orenburg

Email: diabet@esoo.ru

Russian Federation

Elena Ivanova

Repiblic hospital named after V.A. Baranov, Petrozavodsk

Email: insulin@medicine.karelia.ru

Russian Federation

Ekaterina Krishtal

Volgograd Regional Clinical Hospital #1, Volgograd

Email: katkiseleva@mail.ru
ORCID iD: 0000-0002-0710-4262
SPIN-code: 1572-1638

Russian Federation

Alla Vachygova

Volgograd Regional Clinical Hospital #1, Volgograd

Email: avachugova@yandex.ru
ORCID iD: 0000-0002-5800-9759
SPIN-code: 7144-2996

Russian Federation

Ekaterina A. Pigarova

Endocrinology Research Centre

Email: kpigarova@gmail.com
ORCID iD: 0000-0001-6539-466X
SPIN-code: 6912-6331
Scopus Author ID: 55655098500
ResearcherId: T-9424-2018

Russian Federation, 11, Dm. Ulyanova street, Moscow, 117036

MD, PhD

Larisa K. Dzeranova

Endocrinology Research Centre

Email: dzeranovalk@yandex.ru
ORCID iD: 0000-0002-0327-4619
SPIN-code: 2958-5555

Russian Federation, 11, Dm. Ulyanova street, Moscow, 117036

ScD

Evgenia I. Marova

Endocrinology Research Center of the Health Ministry

Email: marova-e@mail.ru
ORCID iD: 0000-0002-5130-4157

Russian Federation

MD, PhD

Svetlana D. Arapova

Endocrinology Research Centre

Email: arapova-s@inbox.ru
ORCID iD: 0000-0003-0028-4659
SPIN-code: 3100-4819

Russian Federation, 11 Dm. Ulyanova street, 117036 Moscow

PhD, MD

Elizaveta O. Mamedova

Endocrinology Research Centre

Email: lilybet@mail.ru
ORCID iD: 0000-0002-9783-3599
SPIN-code: 3904-6017

Russian Federation, 11, Dm. Ulyanova street, Moscow, 117036 

MD

Tatiana A. Grebennikova

Endocrinology Research Centre

Email: grebennikova@hotmail.com
ORCID iD: 0000-0003-1413-1549
SPIN-code: 4380-5447

Russian Federation, 11 Dm. Ulyanova street, 117036 Moscow

MD, PhD

Mikhail Borisovich Antsiferov

State Moscow Endocrine Dispensary

Email: antsiferov@rambler.ru
ORCID iD: 0000-0002-9944-2997
SPIN-code: 1035-4773

Russian Federation, 37, Prechistenka st., Moscow, 119034 Russian Federation

MD, PhD, Professor

Alexander V. Dreval

Moscow Area Moscows regional research clinical institute n.a. M.F. Vladimirskiy

Email: dreval@diabet.ru
ORCID iD: 0000-0002-3135-9003
SPIN-code: 5853-3989

Russian Federation, 61/2, Shepkina street, Moscow, 129110

MD, PhD, Professor

Ivan I. Dedov

Endocrinology Research Centre

Email: dedov@endocrincentr.ru
ORCID iD: 0000-0002-8175-7886
SPIN-code: 5873-2280

Russian Federation, 11, Dm. Ulyanova street, Moscow, 117036

MD, PhD, Professor

References

  • Lavrentaki A, Paluzzi A, Wass JAH, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary. 2017;20(1):4-9. doi: 10.1007/s11102-016-0754-x.
  • www.gks.ru. http://www.gks.ru/. Accessed June 7, 2019.
  • Bex M, Abs R, T’Sjoen G, et al. AcroBel – the Belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjects. European Journal of Endocrinology. 2007;157(4):399-409. doi: 10.1530/EJE-07-0358.
  • Sesmilo G, Gaztambide S, et al. Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA). Pituitary. 2013;16(1):115-121. doi: 10.1007/s11102-012-0384-x.
  • Agustsson TT, Baldvinsdottir T, Jonasson JG, et al. The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study. European Journal of Endocrinology. 2015;173(5):655-664. doi: 10.1530/EJE-15-0189.
  • Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, et al. The Mexican Acromegaly Registry: Clinical and Biochemical Characteristics at Diagnosis and Therapeutic Outcomes. The Journal of Clinical Endocrinology & Metabolism. 2016;101(11):3997-4004. doi: 10.1210/jc.2016-1937.
  • Maione L, Chanson P. National acromegaly registries. Best Practice & Research Clinical Endocrinology & Metabolism. March 2019:S1521690X19300077. doi: 10.1016/j.beem.2019.02.001.
  • Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium. The Journal of Clinical Endocrinology & Metabolism. 2006;91(12):4769-4775. doi: 10.1210/jc.2006-1668.
  • Fernandez A, Karavitaki N, Wass JAH. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clinical Endocrinology. 2010;72(3):377-382. doi: 10.1111/j.1365-2265.2009.03667.x.
  • Raappana A, Koivukangas J, Ebeling T, Pirilä T. Incidence of Pituitary Adenomas in Northern Finland in 1992–2007. The Journal of Clinical Endocrinology & Metabolism. 2010;95(9):4268-4275. doi: 10.1210/jc.2010-0537.
  • Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary. 2013;16(4):545-553. doi: 10.1007/s11102-012-0454-0.
  • Maione L, Brue T, Beckers A, et al. Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. European Journal of Endocrinology. 2017;176(5):645-655. doi: 10.1530/EJE-16-1064.
  • Mestron A, Webb S, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). European Journal of Endocrinology. October 2004:439-446. doi: 10.1530/eje.0.1510439.
  • Schöfl C, Franz H, Grussendorf M, et al. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. European Journal of Endocrinology. 2013;168(1):39-47. doi: 10.1530/EJE-12-0602.
  • Bello MO, Garla VV. Gigantism And Acromegaly. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2019. http://www.ncbi.nlm.nih.gov/books/NBK538261/. Accessed June 3, 2019.
  • Anagnostis P, Efstathiadou ZA, Polyzos SA, et al. Acromegaly: presentation, morbidity and treatment outcomes at a single centre: Acromegaly: a single centre experience. International Journal of Clinical Practice. 2011;65(8):896-902. doi: 10.1111/j.1742-1241.2011.02682.x.
  • Arosio M, Reimondo G, Malchiodi E, et al. Predictors of morbidity and mortality in acromegaly: an Italian survey. European Journal of Endocrinology. 2012;167(2):189-198. doi: 10.1530/EJE-12-0084.
  • Vallette S, Ezzat S, Chik C, et al. Emerging trends in the diagnosis and treatment of acromegaly in Canada. Clin Endocrinol. 2013;79(1):79-85. doi: 10.1111/cen.12112.
  • Kwon O, Song YD, Kim SY, Lee EJ, Rare Disease Study Group, Science and Research Committee, Korean Endocrine Society. Nationwide survey of acromegaly in South Korea. Clin Endocrinol. 2013;78(4):577-585. doi: 10.1111/cen.12020.
  • Mercieca C, Gruppetta M, Vassallo J. Epidemiology, treatment trends and outcomes of acromegaly. European Journal of Internal Medicine. 2012;23(8):e206-e207. doi: 10.1016/j.ejim.2012.07.010.
  • Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89(2):667-674. doi: 10.1210/jc.2003-031199.
  • Melmed S, Bronstein MD, Chanson P, et al. A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552-561. doi: 10.1038/s41574-018-0058-5.
  • Dedov II, Molitvoslovova NN, Rozhinskaia LI, Mel’nichenko GA. RUSSIAN ASSOCIATION OF ENDOCRINOLOGISTS NATIONAL PRACTICE GUIDELINES (CLINICAL SIGNS, DIAGNOSIS, DIFFERENTIAL DIAGNOSIS, TREATMENT). Acromegaly. Probl Endokrinol (Mosk). 2013;59(6):4. doi: 10.14341/probl20135964-18.
  • Gadelha MR, Wildemberg LE, Bronstein MD, Gatto F, Ferone D. Somatostatin receptor ligands in the treatment of acromegaly. Pituitary. 2017;20(1):100-108. doi: 10.1007/s11102-017-0791-0.
  • Giustina A, Mazziotti G, Cannavò S, et al. High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study. The Journal of Clinical Endocrinology & Metabolism. 2017;102(7):2454-2464. doi: 10.1210/jc.2017-00142.
  • Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998;83(2):374-378. doi: 10.1210/jcem.83.2.4556.
  • Vilar L, Czepielewsk MA, Naves LA, Rollin GAFS, Casulari LA, Coelho CE. Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy. Endocr Pract. 2007;13(4):396-402. doi: 10.4158/EP.13.4.396.
  • Marazuela M, Ramos-Leví A, Sampedro-Núñez M, Bernabeu I. Cabergoline treatment in acromegaly: pros. Endocrine. 2014;46(2):215-219. doi: 10.1007/s12020-014-0206-1.

Statistics

Views

Abstract - 202

PDF (Russian) - 6

PlumX

Dimensions


Copyright (c) Belaya Z.E., Golounina O.O., Rozhinskaya L.Y., Melnichenko G.A., Isakov M.А., Lutsenko A.S., Alekseeva T., Zenkova T.S., Przhiyalkovskaya E.G., Panyushkina G., Ilukhina O., Ivanova E., Krishtal E., Vachygova A., Pigarova E.A., Dzeranova L.K., Marova E.I., Arapova S.D., Mamedova E.O., Grebennikova T.A., Antsiferov M.B., Dreval A.V., Dedov I.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies